Literature DB >> 24326668

Bioengineering murine mastocytoma cells to produce anticoagulant heparin.

Leyla Gasimli1, Charles A Glass, Payel Datta, Bo Yang, Guoyun Li, Trent R Gemmill, Jong Youn Baik, Susan T Sharfstein, Jeffrey D Esko, Robert J Linhardt.   

Abstract

Heparin (HP), an important anticoagulant polysaccharide, is produced in a complex biosynthetic pathway in connective tissue-type mast cells. Both the structure and size of HP are critical factors determining the anticoagulation activity. A murine mastocytoma (MST) cell line was used as a model system to gain insight into this pathway. As reported, MST cells produce a highly sulfated HP-like polysaccharide that lacks anticoagulant activity (Montgomery RI, Lidholt K, Flay NW, Liang J, Vertel B, Lindahl U, Esko JD. 1992. Stable heparin-producing cell lines derived from the Furth murine mastocytoma. Proc Natl Acad Sci USA 89:11327-11331). Here, we show that transfection of MST cells with a retroviral vector containing heparan sulfate 3-O-sulfotransferase-1 (Hs3st1) restores anticoagulant activity. The MST lines express N-acetylglucosamine N-deacetylase/N-sulfotransferase-1, uronosyl 2-O-sulfotransferase and glucosaminyl 6-O-sulfotransferase-1, which are sufficient to make the highly sulfated HP. Overexpression of Hs3st1 in MST-10H cells resulted in a change in the composition of heparan sulfate (HS)/HP and CS/dermatan sulfate (DS) glycosaminoglycans. The cell-associated HS/HP closely resembles HP with 3-O-sulfo group-containing glucosamine residues and shows anticoagulant activity. This study contributes toward a better understanding of the HP biosynthetic pathway with the goal of providing tools to better control the biosynthesis of HP chains with different structures and activities.

Entities:  

Keywords:  heparan sulfate; heparin; mastocytoma; proteoglycan; sulfotransferase

Mesh:

Substances:

Year:  2013        PMID: 24326668      PMCID: PMC3919470          DOI: 10.1093/glycob/cwt108

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  35 in total

Review 1.  Functions of cell surface heparan sulfate proteoglycans.

Authors:  M Bernfield; M Götte; P W Park; O Reizes; M L Fitzgerald; J Lincecum; M Zako
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

Review 2.  Order out of chaos: assembly of ligand binding sites in heparan sulfate.

Authors:  Jeffrey D Esko; Scott B Selleck
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

3.  2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity.

Authors:  Robert J Linhardt
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

4.  Cloning, sequencing, and expression of the gene from bacillus circulans that codes for a heparinase that degrades both heparin and heparan sulfate.

Authors:  Eiichi Yoshida; Shinji Arakawa; Taizo Matsunaga; Shigeki Toriumi; Shinji Tokuyama; Kiyoshi Morikawa; Yasutaka Tahara
Journal:  Biosci Biotechnol Biochem       Date:  2002-09       Impact factor: 2.043

Review 5.  Production and chemical processing of low molecular weight heparins.

Authors:  R J Linhardt; N S Gunay
Journal:  Semin Thromb Hemost       Date:  1999       Impact factor: 4.180

6.  Staining of mast cell acid glycosaminoglycans in ultrathin sections by ruthenium red.

Authors:  G T Gustafson; E Pihl
Journal:  Nature       Date:  1967-11-18       Impact factor: 49.962

7.  Degradation of heparin in mouse mastocytoma tissue.

Authors:  S Ogren; U Lindahl
Journal:  Biochem J       Date:  1971-12       Impact factor: 3.857

8.  Structural characterization of pharmaceutical heparins prepared from different animal tissues.

Authors:  Li Fu; Guoyun Li; Bo Yang; Akihiro Onishi; Lingyun Li; Peilong Sun; Fuming Zhang; Robert J Linhardt
Journal:  J Pharm Sci       Date:  2013-03-21       Impact factor: 3.534

9.  Isolation and characterization of glycosaminoglycans from the Furth murine mastocytoma.

Authors:  R E Hurst; N Nakamura; S S West
Journal:  Prep Biochem       Date:  1978

Review 10.  Critical role of mast cells in inflammatory diseases and the effect of acute stress.

Authors:  Theoharis C Theoharides; David E Cochrane
Journal:  J Neuroimmunol       Date:  2004-01       Impact factor: 3.478

View more
  3 in total

1.  Bioengineered heparin: is there a future for this form of the successful therapeutic?

Authors:  Megan S Lord; John M Whitelock
Journal:  Bioengineered       Date:  2014-06-05       Impact factor: 3.269

Review 2.  Engineered heparins as new anticoagulant drugs.

Authors:  Deepika Vaidyanathan; Asher Williams; Jonathan S Dordick; Mattheos A G Koffas; Robert J Linhardt
Journal:  Bioeng Transl Med       Date:  2016-11-21

3.  SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.

Authors:  Thomas Mandel Clausen; Daniel R Sandoval; Charlotte B Spliid; Jessica Pihl; Hailee R Perrett; Chelsea D Painter; Anoop Narayanan; Sydney A Majowicz; Elizabeth M Kwong; Rachael N McVicar; Bryan E Thacker; Charles A Glass; Zhang Yang; Jonathan L Torres; Gregory J Golden; Phillip L Bartels; Ryan N Porell; Aaron F Garretson; Logan Laubach; Jared Feldman; Xin Yin; Yuan Pu; Blake M Hauser; Timothy M Caradonna; Benjamin P Kellman; Cameron Martino; Philip L S M Gordts; Sumit K Chanda; Aaron G Schmidt; Kamil Godula; Sandra L Leibel; Joyce Jose; Kevin D Corbett; Andrew B Ward; Aaron F Carlin; Jeffrey D Esko
Journal:  Cell       Date:  2020-09-14       Impact factor: 41.582

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.